Midazolam Autoinjector

The Defense Logistics Agency Troop Support Medical is seeking potential sources for a Midazolam Injection CIV Autoinjector, a critical medical device designed to treat seizures caused by nerve agents. The solicitation aims to replace the current Convulsant Antidote Nerve Agent (CANA) autoinjector with a new single-dose, pre-filled autoinjector containing 10mg/0.7mL of Midazolam for patients 18 months and older. Manufacturers must have FDA approval for the autoinjector prior to the solicitation closing date and demonstrate capabilities in biological product manufacturing. Interested companies are required to submit detailed market research information to Jessica De La Hoz by May 28, 2025, including manufacturing capabilities, FDA registration, production capacities, storage requirements, and potential pricing. The evaluation will focus on companies' ability to meet technical specifications, production capabilities, and regulatory compliance.

The procurement is structured as an indefinite delivery, indefinite quantity (IDIQ) contract with a one-year base term and four one-year option terms. The total potential quantity ranges from 675,000 to 3,662,400 autoinjectors, with a proposed monthly delivery of up to 60,960 units to DLA Distribution Susquehanna in New Cumberland, PA. The contract falls under NAICS code 325414 for Biological Product Manufacturing, with small businesses defined as those employing less than 1,250 people. There is no specific set-aside designation for this procurement, indicating it is open to both small and large manufacturers. The solicitation will be posted on https://www.dibbs.bsm.dla.mil// and requires vendors to have storage capabilities between 15-30°C and provide products with a 36-month expiration date. Potential bidders must demonstrate the ability to meet these stringent medical supply chain requirements.